@article{oai:nagasaki-u.repo.nii.ac.jp:00027733,
 author = {Fujioka, Machiko and Itonaga, Hidehiro and Furumoto, Takafumi and Sakaki, Chika and Sakamoto, Hikaru and Kato, Takeharu and Horai, Makiko and Taguchi, Masataka and Sawayama, Yasushi and Taguchi, Jun and Imaizumi, Yoshitaka and Yoshida, Shinichiro and Moriuchi, Yukiyoshi and Miyazaki, Yasushi},
 journal = {Transplant Immunology},
 month = {Sep},
 note = {Donor lymphocyte infusion (DLI) is a therapeutic modality for relapsed hematological malignancies after allogeneic hematopoietic stem cell transplantation. We retrospectively analyzed non-infectious pulmonary complications (non-IPCs) following DLI therapy in 41 post-transplant patients with hematological malignancies, and found that 7 developed post-DLI non-IPCs. The 6-year cumulative incidence of non-IPCs was 18.0%. In these patients, non-IPCs were classified into three subtypes: acute respiratory distress syndrome (ARDS), nonspecific interstitial pneumonia (NSIP), and bronchiolitis obliterans syndrome (BOS). The median intervals from the last date of DLI to the development of ARDS and BOS were 12 days (range, 12–14) and 9.4 months (range, 2.6–61.8), respectively; the intervals between DLI and the development of NSIP were 3.5 and 24.7 in 2 patients. Regarding the status of GVHD before the diagnosis with ARDS, 2 out of 3 patients showed the progression of acute GVHD following DLI therapy. One out of 2 patients with NSIP and all 3 patients with BO had chronic GVHD symptoms prior to the development of non-IPCs. In our cohort, 1 patient died of the progression of NSIP. In conclusion, the present study showed the clinical features of non-IPCs following DLI, suggesting the importance of careful followups for non-IPCs in post-DLI patients., Transplant Immunology, 75, art. no. 101707; 2022},
 title = {Clinical features of non-infectious pulmonary complications after donor lymphocyte infusion in post-transplant patients: The Nagasaki Transplant Group Experience},
 volume = {75},
 year = {2022}
}